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Mitoxantrone is an anti-tumour drug, developed by a rational
modification of the parent 1,4-dehydroxy analogue, ametantrone
(for review see Cheng et al, 1989). The mechanism of action of
mitoxantrone and other aminoalkyl anthracenediones involves
multiple effects on cellular DNA but strong DNA binding through
intercalation is believed to be responsible for the pharmacological
activity of these agents (for review see Cheng et al, 1989; Fry,
1991). Mitoxantrone also inhibits DNA topoisomerase II and
targetting of this enzyme contributes to the anti-tumour effect of
this drug at least in some cellular systems (Smith et al, 1990 and
references therein). However, several mitoxantrone analogues
have been identified which do not inhibit topoisomerase II but
still exhibit high anti-tumour activity (Glisson et al, 1990).
Structure–activity relationship studies showed the crucial role of
diaminoalkyl group in side chains of anthracenediones for the
biological activity of these compounds (for review see Cheng et al,
1989) but the importance of this group for any of the proposed
mechanisms of action of anthracenediones is not clear.
Our previous studies have shown that anthracyclines, such as
doxorubicin and daunorubicin, induce DNA cross-links in tumour
cells (Konopa, 1983; Skladanowski and Konopa, 1994a) and the
induction of DNA cross-links seems to be relevant for biological
ativity of these drugs (Skladanowski and Konopa, 1994b).
Anthracenediones may be regarded as structural analogues of
anthracyclines, and mitoxantrone and ametantrone are readily
metabolized both in vitro and in vivo (Ehninger et al, 1990 and
references therein) to chemically reactive species which bind
DNA (Reszka et al, 1989; Mewes et al, 1993). The present study
explored the possibility that mitoxantrone and ametantrone may
form interstrand cross-links in DNA of tumour cells.
MATERIALS AND METHODS
Chemicals
All reagents were from Sigma (Poznan, Poland); [14C]-thymidine
was from Amersham International (Amersham, UK.).
Drugs
Mitoxantrone and ametantrone were synthesized in our
Department, and the biologically inactive analogue of mito-
xantrone NSC 321458 (for chemical structures see Figure 1) was
provided by the National Cancer Institute (Natural Products
Branch, Bethesda, MD, USA) by courtesy of Dr Matthew
Suffness.
Cell culture and media
HeLa S3 cells, the media, glutamine and fetal calf serum (FCS)
were from Gibco Europe Ltd (Paisley, UK). Antibiotics were from
Serva (Heidelberg, Germany). Cells were grown in a monolayer
culture in MEM (minimal essential media) supplemented with 5%
FCS and antibiotics. The cytotoxicity of anthracenediones was
determined after 3-h drug treatment followed by 96-h post-incuba-
tion by the MTT 3-(4,5-dimethylthiazal-2-yl)-2,5-diphenyltetra-
zolium bromide) assay. The EC50 dose (drug concentration
resulting in 50% inhibition of MTT dye formation, compared to
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Figure 1 Chemical structure of the studied anthracenediones
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controls) was calculated directly from semi-logarithmic
dose–response curves.
Determination of interstrand DNA cross-links
HeLa S3 cells (2.5 ´ 106 cells 10 ml–1) were exposed to various
concentrations of drugs for 3 h at 37°C. Interstrand DNA cross-
links were determined by the procedure described in detail previ-
ously (Skladanowski and Konopa, 1994a). Briefly, after lysis of
cells in lysis buffer (6.8 M sodium perchlorate, 1 mM EDTA, 0.2%
lauroyl sarcosine, 20% v/v methanol, pH 7) cellular DNA was
denatured by heating samples at 50°C for 30 min and allowing
them to renature by rapid dilution with 20 ml of ice-cold acetate
buffer (0.04 M sodium acetate, 0.4 M sodium chloride, 5 mM zinc
acetate, pH 4.4) and cooling in methanol–ice mixture (–18°C,
1 min). The percentage of interstrand cross-linked DNA was
determined using nuclease S1 assay as described previously
(Konopa, 1983). The fraction of renatured double-stranded DNA
from untreated cells did not exceed 10–15%. The fraction of cross-
linked DNA was calculated according to the formula:
where RFtreat and RFcontr are fractions of renatured DNA in drug-
treated and non-treated cells respectively.
For cell-free system studies, drugs were added directly to the
cell lysates prepared as described above and incubated protected
from light at 37°C for 3 h. The cellular DNA was then denatured
and renatured and fractions of cross-linked DNA were determined
as described above. For thermal denaturation, samples were heated
at 95°C, 15 min and cooled in methanol–ice bath for 2 min. For
alkaline denaturation, 0.12 ml 1 M sodium hydroxide was gently
added to give 30 mM final concentration and after 1-h incubation
in the dark at room temperature the samples were neutralized with
0.12 ml 1 M hydrochloric acid (HCl) before DNA cross-linking
measurements.
In some experiments, cell lysates were deproteinized before
DNA denaturation. Following treatment with the drugs, cells were
suspended in 400 ml of lysing buffer (50 mM Tris–HCI, pH 7.5, 5
mM EDTA, 0.5% lauroyl sarcosine, 0.5 mg ml–1 proteinase K) and
incubated at 37°C for 2 h. Then 3.6 ml lysing solution (see above)
was added and lysis was carried out at 37°C for an additional 1 h
and DNA cross-links were determined as described above.
Topoisomerase II-associated DNA damage in intact
cells
DNA–protein complexes were quantified by the potassium
chloride (KCl)-SDS (sodium dodecyl sulphate) co-precipitation
assay as described (Zwelling et al, 1989). Data are expressed as
the ratio of [3H]DNA to [14C]protein, with protein being an internal
standard for the exact number of cells used.
RESULTS
Interstrand DNA cross-linking in DNA of tumour cells
Exposure of HeLa S3 to either mitoxantrone or ametantrone
resulted in an increase in the fractions of cross-linked DNA (FCR)
with increasing concentration of the drugs (Figure 2, A and B,
closed symbols). A close structural analogue of mitoxantrone,
compound NSC 321458, did not induce any interstrand DNA
crosslinking in HeLa S3 cells even at concentrations as high as
150 mM (Figure 2C, closed symbols). This compound lacks
the distal nitrogen atoms in the side chains (compare chemical
RFtreat-RFcontr
FCR=  ´ 100%
100-RFcontr
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Figure 2 DNA cross-linking induced by mitoxantrone (A), ametantrone (B) and NSC 321458 (C). HeLa S3 cells were incubated with the compounds for 3 h
and fractions of cross-linked DNA were determined by the method described in Materials and Methods without (closed symbols) and with (open symbols)
protein digestion. Points, mean from three independent experiments; bars, s.d
Table 1 Cytotoxic activity against HeLa S3 cells and DNA cross-linking
potency of the studied anthracenediones
Compound EC50 (mM)a DPCmax
b C0 (mM)c
Mitoxantrone 0.2 1.0 9.8
Ametantrone 2.7 0.47 4.1
NSC 321458 > 100 0.24 –
aConcentration inhibiting growth of HeLa S3 cells by 50% compared to non-
treated cells. bRelative level of DNA–protein complexes induced by drugs
(mitoxantrone = 1). cConcentration at which the first DNA cross-link could be
detected.1302 A Skladanowski and J Konopa
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structures in Figure 1) and is not cytotoxic toward HeLa S3 cells
(EC50 > 100 mM). To characterize DNA cross-linking potency of
the studied compounds, we calculated concentration at which the
first cross-link could be detected (C0 concentration) by our
method. This was done by a linear fit of the relationship between
drug concentration and fraction of cross-linked DNA (FCR) and
extrapolation to intercept C0, at 0% of FCR. The C0 values and cyto-
toxic activity (the EC50 concentration), determined in the same
conditions as DNA cross–linking, for all anthracenediones studied
are shown in Table 1.
The lack of DNA cross-linking in cell-free system
Mitoxantrone and ametantrone show high affinity binding to DNA
and increased renaturation of DNA from cells treated with
anthracenediones may result from stabilization of DNA structure
by these drugs due to stable physicochemical intercalative
complexes with DNA. To distinguish between physicochemical
and covalent cross-linking of DNA from drug-treated cells, cell
lysates from untreated HeLa S3 cells were incubated with the
studied compounds at concentration (50 mM) which produced
significant DNA cross-linking in whole cells. Fractions of cross-
linked DNA, determined when the studied anthracenediones were
added directly to the cell lysates for 3 h at 37°C and then processed
as for whole cells, were very low compared to those obtained for
DNA from cells treated with the same concentrations of the drugs
and the same time of treatment (Figure 3). It suggests that strong
physicochemical binding of the studied anthracenediones to DNA
is not responsible for enhanced renaturability of DNA from treated
cells.
Stabilization of DNA–protein complexes by
anthracenediones
Mitoxantrone and ametantrone stabilize topoisomerase II–DNA
cleavable complexes (Smith et al, 1990 and this study). Therefore,
it was possible that increased renaturation of DNA from cells
treated with these compounds stems from DNA–topoisomerase II
complexes which may survive mild denaturation conditions. To
clarify this point, we determined the level of DNA–protein
complexes induced by studied compounds by the K–SDS co-
precipitation assay. As shown in Figure 4, all the anthracenediones
induced DNA–protein complexes with characteristic bell-shaped
dose–response curves. Interestingly, even a biologically inactive
derivative, NSC 321458, produced measurable level of
DNA–protein complexes (about twofold lower than ametantrone)
although this compound is only marginally cytotoxic (> 80%
viability) at concentrations up to 100 mM. The effect of stabiliza-
tion of DNA–protein complexes by studied drugs on DNA renatu-
ration was assessed by including deproteinization step in the
procedure for DNA cross-links measurements. When proteins in
cellular lysates were digested by proteinase K before DNA denat-
uration, increased fraction of renaturable DNA from cells treated
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Figure 3 Fractions of cross-linked DNA determined in HeLa S3 cells
(hatched bars) and cell lysates (solid bars) treated with the studied
anthracenediones. The cells and cell lysates were incubated with
anthracenediones at 50 mM for 3 h at 37°C and fractions of cross-linked DNA
were determined as described in Materials and Methods
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Figure 4 DNA–protein complexes induced by anthracenediones in HeLa
S3 cells. Cells were exposed for 3 h to different doses of mitoxantrone (n),
ametantrone (•) and NSC321458 (t) and the level of DNA–protein
complexes was determined by the K–SDS co-precipitation assay
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Figure 5 Thermal and alkaline instability of DNA cross-links induced by
mitoxantrone in HeLa S3. The cells were treated with the compound at 50 mM
for 3 h at 37°C and fractions of cross-linked DNA were determined as
described in Materials and Methods with various denaturation conditionsMitoxantrone and ametantrone cross-link DNA of tumour cells 1303
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with drugs was still observed for mitoxantrone and ametantrone,
and was quite similar to the results obtained when protein diges-
tion was omitted (Figure 2, open symbols).
Thermal and alkaline instability of DNA cross-links
No DNA cross-links could be observed when DNA from cells
treated with mitoxantrone was denatured in alkaline conditions
(pH 12, 1 h); however, they partially resisted elevated temperature
(Figure 5). The FCR values obtained for DNA from cells treated
with 50 mM mitoxantrone and denatured at 95°C for 5 min are
about 50% the value obtained when DNA denaturation was
performed at lower temperature according to the method used
throughout these studies (50°C, 30 min), whereas only marginal
DNA cross-linking was observed when thermal denaturation of
DNA was prolonged to 15 min (Figure 5). Similar results were
obtained for ametantrone (data not shown).
DISCUSSION
We have found that mitoxantrone and ametantrone produced DNA
cross-links in HeLa S3 cells in a concentration-dependent manner.
First, DNA cross-links induced by mitoxantrone and ametantrone
could be observed at concentrations of about 5–10 mM. Previous
studies showed that peak plasma concentration of mitoxantrone in
patients treated with this drug is about 10 mM (5–13 mM) and
remains constant for about 20 h after drug treatment (Sundman-
Engberg et al, 1993). It follows that DNA cross-links formed by
anthracenediones could be detected by our method at concentra-
tions close to those physiologically achieveable.
Mitoxantrone and ametantrone did not produce any DNA cross-
linking when added directly to cell lysates, in which cellular
enzymes were inactivated. From this observation two conclusions
can be drawn. First, the increased renaturation of DNA from cells
treated with aminoanthraquinones was not the effect of their stabi-
lization of DNA structure by intercalation, and second, that meta-
bolic activation of these two compounds is required for covalent
binding and cross-linking of cellular DNA. Mitoxantrone and
ametantrone possess no reactive groups which bind covalently to
DNA but these compounds have been shown to be readily metab-
olized in vitro and in whole cells (see Ehninger et al, 1990 and
references therein). Oxidation of mitoxantrone results in covalent
binding of the drug to DNA and thiols (Reszka et al, 1989; Mewes
et al, 1993; Dackiewicz et al, 1995) and intramolecular cross-
linking of plasmid DNA in vitro (Fisher and Patterson, 1990).
A close structural analogue of mitoxantrone, NSC 321458,
which is biologically inactive, did not produce any DNA cross-
links in HeLa S3 cells. In contrast, this compound stimulated low
levels of DNA–protein complexes in whole cells, only one-half of
those observed for ametantrone. It would suggest that the effect of
NSC 321458 on topoisomerase II-associated DNA complexes
cannot fully explain the lack of biological activity of this
compound toward HeLa S3 cells. NSC 321458 differs from mito-
xantrone in the lack of the distal amino groups in the side chains. It
may suggest that alkyldiamine residues are involved in covalent
binding and DNA cross-linking by mitoxantrone and ametantrone.
Our preliminary results showed that activation of mitoxantrone by
rat liver microsomes leads to formation of reactive hydroxylamine
residues (unpublished results). Therefore, covalent binding to
DNA by enzymatically activated alkylamine groups could explain
the essential role of these moieties for biological activity of
aminoanthraquinones shown by several authors (see Cheng et al,
1989 and references therein).
The fact that alkyldiamine residue may be of the primary impor-
tance for biological activity and DNA crosslinking ability of
mitoxantrone suggested to us that attachment of alkyldiamine
moiety to other planar polycyclic chromophore favouring inter-
calative binding to DNA should yield new anti-tumour
compounds. The role of the planar nucleus would be to position
of the compound within the DNA structure, and structural modifi-
cations of the chromophore system should lead to enhanced reac-
tivity of alkyldiamine residue during metabolic activation by
cellular enzymes. Accordingly, several new groups of very active
anti-tumour compounds were synthesized in our laboratory,
derivatives of imidazoacridone (Cholody et al, 1990a) and
triazoloacridone (Cholody et al, 1990b).
We observed that ametantrone is a more potent DNA cross-
linking agent than mitoxantrone although the latter is more than
ten times more cytotoxic toward HeLa S3 cells (compare C0 and
EC50 values for ametantrone and mitoxantrone in Table 1). On the
other hand, ametantrone produces approximately twofold less
DNA–protein complexes than mitoxantrone (Figure 4 and Table
1). We favour the possibility that overlapping protein-associated
DNA breaks lower renaturation fraction of DNA at concentrations
where both DNA cross-linking and stabilization of DNA–protein
complexes is observed. It would lead to a higher C0 value for
mitoxantrone compared to ametantrone. Further studies are
required to clarify this notion.
DNA cross-links produced by mitoxantrone and ametantrone
resisted only a short exposure to elevated temperature, therefore
they are unlikely to be detected by the methods based on thermal
denaturation of DNA. Additionally, the cross-links were disrupted
at alkaline pH (pH 12, 1 h) and therefore could not be detected by
alkaline elution procedures where DNA is exposed to alkali for a
prolonged period of time (pH 12, about 12 h). For this reason, in
this study we used a new mild procedure developed in our labora-
tory (Skladanowski and Konopa, 1994a). Validity of this method
was proved by measuring DNA cross-linking induced by mito-
mycin C, a classical bifunctional DNA alkylator (data not shown).
In conclusion, we here show that two aminoanthraquinone
drugs, mitoxantrone and ametantrone, induce covalent DNA
cross-links in HeLa S3 cells at concentrations close to those clini-
cally achievable. The formation of DNA cross-links by these two
drugs was not observed in cell lysated with inactivated cellular
enzymes, suggesting that metabolic activation is necessary for
DNA cross-linking to occur. The significance of DNA cross-
linking by mitoxantrone and ametantrone for their biological
activity is not clear at this point and is a subject of ongoing studies
in our laboratory.
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